Efficacy of Esaxerenone Plus a Renin–Angiotensin System Inhibitor or Calcium Channel Blocker for Nocturnal Hypertension: A Post Hoc Analysis
American Journal of Hypertension · 2025
DOI: 10.1093/ajh/hpaf048 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift American Journal of Hypertension, 2025. Verfasst von Kazuomi Kario und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Shimotsuke, Japan. Hauptthemen laut MEDLINE: Hypertension, Calcium Channel Blockers, Blood Pressure, Antihypertensive Agents. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
BACKGROUND Nocturnal blood pressure (BP) is superior to daytime BP in predicting cardiovascular mortality. It is of clinical relevance to evaluate the effect of esaxerenone combination therapy on nighttime BP in patients with uncontrolled hypertension. METHODS A post hoc analysis of a multicenter, open-label, phase 3 study evaluated the nighttime BP-lowering effects of esaxerenone as monotherapy or in combination with a calcium channel blocker (CCB) or renin–angiotensin system inhibitor (RASi) in Japanese patients with uncontrolled hypertension. In addition, the effect on N-terminal pro B-type natriuretic peptide (NT-proBNP), a known biomarker of cardiovascular disease prognosis, was evaluated. RESULTS In total, 270 patients were included in this analysis (172, 49, and 49 patients in the monotherapy, CCB, and RASi groups, respectively). The 24-hour ambulatory systolic BP reduction from baseline was − 10.0, − 6.0, and − 17.0 mm Hg in the monotherapy, CCB, and RASi groups, respectively. Nighttime systolic BP decreased significantly from baseline to week 28 in all groups (P < 0.001 each); the RASi group showed the greatest change (− 20.6 mm Hg). NT-proBNP decreased significantly in all three treatment groups. CONCLUSIONS Esaxerenone when used in combination with a CCB or RASi, but especially when used in combination with a RASi, may be a useful treatment option for patients with uncontrolled hypertension to control nocturnal BP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Shimotsuke, Japan.
- Division of Nephrology, Endocrinology and Vascular Medicine, Department of Medicine, Tohoku University School of Medicine, Sendai, Japan.
- Katta General Hospital, Shiroishi, Japan.
- Department of Endocrinology, Metabolism and Nephrology, Keio University School of Medicine, Tokyo, Japan.
- Center for Preventive Medicine, Keio University, Tokyo, Japan.
- Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
ORCID-Profile: Kazuomi Kario, Sadayoshi Ito, Hiroshi Itoh
Zitieren
APA
Kario, K., Ito, S., Itoh, H., Rakugi, H., Okuda, Y., & Yamakawa, S. (2025). Efficacy of Esaxerenone Plus a Renin–Angiotensin System Inhibitor or Calcium Channel Blocker for Nocturnal Hypertension: A Post Hoc Analysis. American Journal of Hypertension. https://doi.org/10.1093/ajh/hpaf048
Vancouver
Kario K, Ito S, Itoh H, Rakugi H, Okuda Y, Yamakawa S. Efficacy of Esaxerenone Plus a Renin–Angiotensin System Inhibitor or Calcium Channel Blocker for Nocturnal Hypertension: A Post Hoc Analysis. American Journal of Hypertension. 2025. doi:10.1093/ajh/hpaf048
BibTeX
@article{Kario2025,
author = {Kario, Kazuomi and Ito, Sadayoshi and Itoh, Hiroshi and Rakugi, Hiromi and Okuda, Yasuyuki and Yamakawa, Satoru},
title = {Efficacy of Esaxerenone Plus a Renin–Angiotensin System Inhibitor or Calcium Channel Blocker for Nocturnal Hypertension: A Post Hoc Analysis},
journal = {American Journal of Hypertension},
year = {2025},
doi = {10.1093/ajh/hpaf048}
}
EUVIMED